SIZE GLOBAL PURCHASING
1 mg, 5 mg, 10 mg, 100mg , 500mg, 1kg
Chemical Name (4-Bromo-3,6-dimethoxybenzocyclobut en-1-yl)methylamine hydrobromide
M. Wt 353.05
Purity >99 %
Solubility Soluble to 25 mM in water and to 100 mM in DMSO
Storage Store at +4°C
TCB2 is an agonist of serotonin 5-HT2A receptor.
TCB-2,(4-Bromo-3,6-dimethoxybenzocyclobut en-1-yl)methylamine hydrobromide
TCB-2 is a high affinity 5-HT2A receptor agonist that potently stimulates IP3 accumulation in NIH3T3 cells stably expressing rat 5-HT2A receptors with an EC50 value of 36 nM.
The selective 5-HT2A agonist TCB2 at 30 nM produces a marked shift to the right in the competition curve obtained with the 5-HT1A receptor agonist ipsapirone from [3H]-8-OHDPAT binding sites in both areas of the brain. A significant increase in the mean Ki value is obtained with TCB2, demonstrating a reduction in the affinity of the high-affinity 5-HT1A agonist binding sites by the 5-HT2A agonist in both regions. In the case of hippocampus, there are also indications for antagonistic effects of ketanserin.
In an initial dose-response study, TCB2 (0.5, 1.0, and 2.5 mg/kg) and DOI (0.5, 1.0, 2.5, and 5.0 mg/kg) induce head twitches in C57BL/6J mice in a dose-dependent manner compared to vehicle. Head twitches induced by TCB2 and DOI are similar across the doses, with the exception that at the highest dose (5.0 mg/kg), TCB2 induces half as many head twitches as does DOI (p=0.021). Confirming 5-HT2A mediation of the head twitch response, in two separate studies, pretreatment with the selective 5-HT2A antagonist MDL 11,939 (1.0 mg/kg) block head twitches induced by DOI (2.5 mg/kg) and by TCB2 (2.5 mg/kg; p<0.0001). Compared to vehicle, corticosterone levels are increased following TCB2 (5.0 mg/kg, p=0.01; 10.0, p=0.012; with a trend following 2.5 mg/kg, p=0.079) and DOI (10.0 mg/kg, p=0.035).